Abstract
This review presents sleep disturbances and their underlying pathophysiology in three categories of neurodegenerative disorders namely tauopathies, synucleinopathies, and Huntingtons disease (HD) and prion-related diseases. Sleep abnormalities are a major and early feature of neurodegenerative disorders, especially for synucleinopathies, HD and prion-related diseases, in which the sleep-related brainstem regions are severely altered and impaired sooner than in most of the tauopathies. In synucleinopathies, HD and prion-related diseases, specific sleep disturbances, different from those observed in tauopathies, are considered as core manifestations of the disease and in some cases, as preclinical signs. For this reason, the evaluation of sleep components in these neurodegenerative disorders may be useful to make a diagnosis and to assess the efficacy of pharmacotherapy. Since sleep disruption may occur early in the course of neurodegeneration, sleep disturbance may serve as groundwork to study the efficacy of neuroprotective agents to prevent or delay the development of a full-blown neurodegenerative disorder. The cause of sleep disturbances in neurodegenerative disorders may be attributed to several factors, including age-related modifications, symptoms of the disease, comorbid conditions and the neurodegenerative process itself.
Keywords: Neurodegenerative disorders, sleep, electroencephalography, tauopathies, synucleinopathies, prion-related diseases, Alzheimer's disease, Parkinson's disease
Current Pharmaceutical Design
Title: Neurobiology of Sleep Disturbances in Neurodegenerative Disorders
Volume: 14 Issue: 32
Author(s): J.-F. Gagnon, D. Petit, V. Latreille and J. Montplaisir
Affiliation:
Keywords: Neurodegenerative disorders, sleep, electroencephalography, tauopathies, synucleinopathies, prion-related diseases, Alzheimer's disease, Parkinson's disease
Abstract: This review presents sleep disturbances and their underlying pathophysiology in three categories of neurodegenerative disorders namely tauopathies, synucleinopathies, and Huntingtons disease (HD) and prion-related diseases. Sleep abnormalities are a major and early feature of neurodegenerative disorders, especially for synucleinopathies, HD and prion-related diseases, in which the sleep-related brainstem regions are severely altered and impaired sooner than in most of the tauopathies. In synucleinopathies, HD and prion-related diseases, specific sleep disturbances, different from those observed in tauopathies, are considered as core manifestations of the disease and in some cases, as preclinical signs. For this reason, the evaluation of sleep components in these neurodegenerative disorders may be useful to make a diagnosis and to assess the efficacy of pharmacotherapy. Since sleep disruption may occur early in the course of neurodegeneration, sleep disturbance may serve as groundwork to study the efficacy of neuroprotective agents to prevent or delay the development of a full-blown neurodegenerative disorder. The cause of sleep disturbances in neurodegenerative disorders may be attributed to several factors, including age-related modifications, symptoms of the disease, comorbid conditions and the neurodegenerative process itself.
Export Options
About this article
Cite this article as:
Gagnon J.-F., Petit D., Latreille V. and Montplaisir J., Neurobiology of Sleep Disturbances in Neurodegenerative Disorders, Current Pharmaceutical Design 2008; 14 (32) . https://dx.doi.org/10.2174/138161208786549353
DOI https://dx.doi.org/10.2174/138161208786549353 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
RAGE and its Ligands in Retinal Disease
Current Molecular Medicine Chemistry and Biochemistry of Oxidative Stress in Neurodegenerative Disease
Current Medicinal Chemistry Human Pluripotent Stem Cells in Neurodegenerative Diseases: Potentials, Advances and Limitations
Current Stem Cell Research & Therapy mGlu5, Dopamine D<sub>2</sub> and Adenosine A<sub>2A</sub> Receptors in L-DOPA-induced Dyskinesias
Current Neuropharmacology Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease
Current Pharmaceutical Design Predicting Dementia Due to Alzheimer’s Disease and Behavioral Variant Frontotemporal Dementia Using Algorithms with the Addenbrooke’s Cognitive Examination-Revised Subscores Combined with Sociodemographic Factors
Current Alzheimer Research Inhibitory Mechanism of An Anticancer Drug, Bexarotene Against Amyloid β Peptide Aggregation: Repurposing Via Neuroinformatics Approach
Current Pharmaceutical Design Patent Selections
Recent Patents on Food, Nutrition & Agriculture The Reification of the Clinical Diagnosis of Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) as an Immune and Oxidative Stress Disorder: Construction of a Data-driven Nomothethic Network and Exposure of ME/CFS Subgroups
Current Topics in Medicinal Chemistry Neurochemical Signaling in Depression: Impact of Target-Based Pharmaceuticals
Current Drug Therapy The Nearest-Neighbor Effect on Random-Coil NMR Chemical Shifts Demonstrated Using a Low-Complexity Amino-Acid Sequence
Protein & Peptide Letters The Putative Use of Lithium in Alzheimer’s Disease
Current Alzheimer Research Meet the Editorial Board Member
Current Neuropharmacology Nrf2 Mediates Effect of Resveratrol in Ischemia-reperfusion Injury
Current Molecular Pharmacology Role of Sirtuins and Calorie Restriction in Neuroprotection: Implications in Alzheimers and Parkinsons Diseases
Current Pharmaceutical Design Catalytic DNA: A Novel Tool for Gene Suppression
Current Drug Targets Extrasynaptic GABA<sub>A</sub> Receptors in the Brainstem and Spinal Cord: Structure and Function
Current Pharmaceutical Design 2-Aminoethyldiphenyl Borinate: A Multitarget Compound with Potential as a Drug Precursor
Current Molecular Pharmacology A Key Role for Connexin Hemichannels in Spreading Ischemic Brain Injury
Current Drug Targets The Role of α5 GABA<sub>A</sub>Receptor Agonists in the Treatment of Cognitive Deficits in Schizophrenia
Current Pharmaceutical Design